- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanostart (OTCQX: NASRY)-holding MagForce AG (FSE:MF6), a leading medical technology company focusing on nanomedicine in oncology, announced that Merchant Securities Limited has initiated research coverage on the company and published its first report. The report gives a buy recommendation and is available upon request from MagForce AG and Merchant Securities Limited or at tinyurl.com/czmb5uu.
"We are very pleased that Merchant Securites has taken up coverage of MagForce. The comprehensive report gives investors an independent view of the company, our novel technology for the treatment of brain tumors, and perspectives on our future growth and development" said Dr. Andreas Jordan, Founder and CSO at MagForce. "Merchant's head life science analyst, Dr. Navid Malik, has been following MagForce for some time and is a highly regarded equity research analyst with over fifteen years' experience in the pharmaceutical field, specifically in the area of oncology."
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information please visit: www.nanostart.de.
MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For further information please visit: www.magforce.com
About NanoTherm® therapy:
NanoTherm® therapy involves the direct injection of magnetic nanoparticles into the tumor and their subsequent heating by an alternating magnetic field. The water-soluble nanoparticles are approximately 15 nanometers in diameter and contain an iron oxide core with an aminosaline coating, which causes the particles to agglomerate following injection. The particles are then activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced within the tumor. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Duerr
Head of Corporate Communications
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016